Patient P-01488
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
52%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S12
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 59 GI-04 recommended — GI Support Protocol GI-04
- Day 60 Patient accepted — Started GI-04 in the companion
- Day 68 GI symptom burden −18% vs expected — GI Support Protocol GI-04
- Day 69 ME-01 recommended — Monitoring Escalation ME-01
- Day 70 Patient accepted — Started ME-01 in the companion
- Day 73 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 74 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- GI instability-12
- Inflammatory activity-4
- Nutritional resilience+4
What helped?
- GI Support Protocol GI-04Day 59Result: symptom burden −18%
- Monitoring Escalation ME-01Day 69Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
56%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 33/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 82 bpm
- WearableShort sleep window
- Inflammatory signalling ↓25
- BloodInflammatory load index 52
- Drug metabolism and exposure ↑20
- BloodToxicity index 52
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 54 ms
- Sleep
- 5.8 h
- Steps
- 4,213
- Resting HR
- 83 bpm
Daily log: GI score 42, nutritional resilience 40, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01494 | 48% | S14 | GI-04 | improved | 42 |
| P-01891 | 48% | S14 | SC-12 | improved | 41 |
| P-01403 | 47% | S14 | GI-04 | improved | 49 |
| P-01547 | 47% | S13 | GI-04 | improved | 50 |
| P-01360 | 44% | S14 | GI-04 | improved | 52 |
| P-01413 | 44% | S14 | GI-04 | improved | 44 |
| P-01423 | 43% | S19 | GI-04 | improved | 44 |
| P-01452 | 43% | S02 | GI-04 | improved | 46 |
| P-01675 | 43% | S14 | NP-02 | improved | 38 |
| P-01389 | 42% | S14 | SC-12 | improved | 46 |
| P-01539 | 42% | S14 | GI-04 | improved | 43 |
| P-01368 | 41% | S14 | GI-04 | improved | 53 |